Fast-Acting Insulin Aspart in Patients with Type1 Diabetes in Real-World Clinical Practice: A Noninterventional, Retrospective Chart and Database Study.

Abstract

This study utilized continuous glucose monitoring data to analyze the effects of switching to treatment with fast-acting insulin aspart (faster aspart) in adults with type1 diabetes (T1D) in clinical practice. A noninterventional database review was conducted in Sweden among adults with T1D using multiple daily injection (MDI) regimens who had switched to treatment with faster aspart as part of basal-bolus treatment. Glycemic data were retrospectively collected during the 26weeks before switching (baseline) and up to 32weeks after switching (follow-up) to assess changes in time in glycemic range (TIR; 70-180mg/dL), mean sensor glucose, glycated hemoglobin (HbA1c) levels, coefficient of variation, time in hyperglycemia (level1, > 180 to ≤ 250mg/dL; level2, > 250mg/dL), and time in hypoglycemia (level1, ≥ 54 to < 70mg/dL; level2, < 54mg/dL) (ClinicalTrials.gov Identifier NCT03895515). Overall, 178 participants were included in the study cohort. The analysis population included 82 individuals (mean age 48.5years) with adequate glucose sensor data. From baseline to follow-up, statistically significant improvements were reported for TIR (mean increase 3.3%-points [approximately 48min/day]; p = 0.006) with clinically relevant improvement (≥ 5%) in 43% of participants. Statistically significant improvements from baseline were observed for mean sensor glucose levels, HbA1c levels, and time in hyperglycemia (levels1 and 2), with no statistically significant changes in time spent in hypoglycemia. Switching to faster aspart was associated with improvements in glycemic control without increasing hypoglycemia in adults with T1D using MDI in this real-world setting.